{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037574","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.839669+00:00","generated_at":"2026-06-12T08:39:49.992057+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fulcrum Therapeutics reports Q2 net loss $23.8M, closes FSHD trial screening, appoints CFO","bullets":["Net loss of $23.8M in Q2 2023, improved from $34.1M in Q2 2022; cash $278.2M.","Screening closed for Phase 3 REACH trial of losmapimod in FSHD; topline data expected Q4 2024.","Alan A. Musso appointed CFO effective Aug 7, 2023; base salary $450K, 40% target bonus, 432,800 stock option.","Licensed global rights from CAMP4 for Diamond-Blackfan Anemia; clinical hold for FTX-6058 remains unresolved.","R&D expenses fell to $17.8M from $25.0M YoY; cash runway into mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037574","json":"https://secwatch.observer/filing/0000950170-23-037574.json","markdown":"https://secwatch.observer/filing/0000950170-23-037574.md","text":"https://secwatch.observer/filing/0000950170-23-037574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000095017023037574/0000950170-23-037574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000095017023037574/fulc-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:39:49.992057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"417657c1602c69ee6f6c2121302675dffa57ac3d","claim":"Fulcrum Therapeutics, Inc. reported financial results for the second quarter of 2023.","evidence_excerpt":"On August 3, 2023, Fulcrum Therapeutics, Inc., or Fulcrum, announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000095017023037574/0000950170-23-037574-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"af0a6d60eb","claim":"Alan A. Musso was appointed as Chief Financial Officer and Treasurer at Fulcrum Therapeutics, Inc..","evidence_excerpt":"On August 2, 2023, Fulcrum’s board of directors, or the Board, appointed Alan A. Musso as Fulcrum’s chief financial officer and treasurer, effective August 7, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000095017023037574/0000950170-23-037574-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}